Tempest Therapeutics, Inc. (TPST) News
Track canonical SquawkNews coverage tagged to TPST, Tempest Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
TPST - Tempest announces development collaboration with senlang Biotechnology for tpst-4003, a cd7-targeted next-generation in vivo Car-t Te
TPST - Tempest announces development collaboration with senlang Biotechnology for tpst-4003, a cd7-targeted next-generation in vivo Car-t Tempest Therapeutics - first patient dosing for tpst-4003 trial expected in Q4 202
GEOPOLITICS | Jul 21, 2026, 11:02 AM UTC
M
ADSK, TPST, ENR, AVO, PWRL: Insider Buys
Insiders purchase shares of ADSK, TPST, ENR, AVO, and PWRL in transactions over $100K
EQUITY | Jun 24, 2026, 09:58 AM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
L
TPST CEO Buys $500k
TPST CEO acquires $500k via purchase agreement
EQUITY | Jun 23, 2026, 09:02 PM UTC
L
TPST: CEO Buys Shares
Tempest Therapeutics CEO and President Angel Matthew P buys 231,482 shares at $2.16
EQUITY | Jun 23, 2026, 08:57 PM UTC